Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 10;5:3. doi: 10.1038/s41541-019-0153-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — In a, licensed seasonal influenza vaccines Fluzone 2014–15 (Lane 1), Fluzone 2015–16 (Lane 2), FluLaval 2013–14 (Lane 3), and FluLaval 2015–16 (Lane 4) were surveyed for the presence of H1 (55 kDa), H3 (55 kDa), NA (75 kDa), NP (56 kDa), and M1 (27 kDa) using antibodies listed in Supplementary Table 2 and indicated to the left. Vaccines were prepared to a final concentration of 2.7 µg of total HA per sample for immunoblot, based on manufacturer-reported hemagglutinin quantity. The proteins within the vaccines were fractionated by SDS-PAGE gel and then analyzed by western blot as described. In b, Fluzone proteins in the 2017–18 vaccine were treated with the enzyme PNGase-F to remove any N-linked glycans present on the HA proteins and then probed for H1 and H3. Untreated vaccines, applied at varying concentrations of HA, are shown on the left and the PNGase-treated vaccines are shown on the right. Molecular weight markers are indicated. A dot represents a molecular weight extrapolated from the mobility of the molecular weight markers.